When IntegriCulture announced on February 9, 2026, that it had turned a profit, the news arrived with a certain irony. Here was a Japanese biotech founded to revolutionize food production—growing meat in bioreactors, no animals required—making its first real money selling cosmetic ingredients and research services. The cultivated wagyu that had once headlined pitch decks? Still years away from regulatory approval. Meanwhile, the company had quietly posted a net profit of JPY 40 million (roughly $255,000) for fiscal year 2025, split evenly between beauty actives derived from cell culture and infrastructure services sold to other startups chasing the same elusive dream.
It wasn't the story CEO Yuki Hanyu had set out to tell a decade earlier. But in an industry still burning through venture capital with little to show for it, profitability—however modest, however unexpected—counted as a win.
The Long Bet
Hanyu's path to cellular agriculture was circuitous, which perhaps explains his willingness to zigzag when conditions demanded it. After earning a chemistry PhD from Oxford in 2010, he spent time in corporate R&D at Toshiba before launching the Shojinmeat Project in 2015, an open-source initiative exploring lab-grown meat. That same year, he and cofounder Ikko Kawashima, who held a PhD in agriculture from Hiroshima University, established IntegriCulture with a broader thesis than most competitors: don't just grow meat. Build the infrastructure everyone else would need.
Hanyu called it "cellular ag infrastructure"—the picks and shovels for an emerging industry. The company would develop proprietary systems like the CulNet conditioned media generator, partner with firms like Sumitomo Riko on bioreactors, and formulate food-grade media with suppliers such as Nacalai Tesque. If cultivated meat took off, IntegriCulture would be the platform provider, not just another startup racing toward regulatory approval for a single product.
By 2020, investors seemed convinced. The company closed a Series A of JPY 800 million (approximately $7.4 million) led by Beyond Next Ventures, with participation from NH Foods, Real Tech Fund, and AgFunder. A bridge round in January 2022 added another $7 million, pushing total capital raised to around $16.4 million. The pitch was ambitious, maybe even prescient.
What no one fully anticipated was how hostile the regulatory landscape would turn.
When Politics Met Protein
By 2023, cultivated meat had become a political lightning rod. Italy moved first, banning production and sale of cultivated meat in December 2023 in what officials framed as a defense of traditional agriculture. Florida followed with a state-level prohibition that took effect October 1, 2024. Even in Japan, where IntegriCulture had hoped for a more receptive environment, progress stalled. Throughout 2026, government subcommittees released draft safety guidelines, but concrete timelines remained frustratingly vague. In a February interview, Hanyu acknowledged the delays with the measured candor of someone who'd learned not to predict regulatory outcomes.
The funding environment reflected the chill. According to the Good Food Institute's 2026 State of the Industry report, cultivated meat and seafood startups raised just $73.9 million globally in 2025—a dramatic contraction from prior years, when hundreds of millions flowed into the sector. Capital was drying up. The path to market was unclear. For IntegriCulture, waiting for regulatory approval meant burning cash with no finish line in sight.
The answer, it turned out, was to stop waiting.
A Side Project Becomes the Main Act
IntegriCulture had launched CELLAMENT in April 2021, almost as an afterthought. The product was an egg-derived cell culture conditioned medium—rich in growth factors, proteins, and antioxidants like lutein and zeaxanthin—marketed for skin repair, anti-inflammatory effects, and UV protection. Initially, it seemed like exactly what it was: a side project, a way to monetize the cell culture platform while the real business of cultivated meat matured.
But as timelines for food applications stretched, cosmetics began to look less like a distraction and more like salvation.
Cosmetics offered something food regulation did not: a framework that already accommodated novel ingredients, consumer demand for biotech-derived actives, and margins high enough to support early-stage production. By 2026, CELLAMENT had been adopted by several Japanese brands. FABIUS launched a "Cell+" finish mask featuring the ingredient in October 2025. OPPEN Cosmetics incorporated it into their ULTIMATE line. BASEPLUS had been using it in their l'oeuf by essensebase products since June 2022. Euglena's CONC line featured CELLAMENT-based formulations on retail shelves.
In August 2025, IntegriCulture signed a memorandum of understanding with Umami Bioworks, a Singapore-based cellular aquaculture startup, to co-develop marine cell-culture-based cosmetics. If fish cells could yield premium beauty ingredients, the technology platform could extend well beyond eggs—perhaps indefinitely.
The company also launched a "Cellag" brand in December 2025 to drive adoption across food, cosmetics, and materials, and introduced a "Cell-Ag Cosmetics" open branding initiative to help consumers identify products using cell-cultured actives. The infrastructure was scaling, just not in the direction originally envisioned.
The Modest Milestone
The February 2026 announcement confirmed what had been building quietly for years. IntegriCulture reported profitability for fiscal year 2025 (October 2024 through September 2025), with revenue split evenly between cosmetic ingredients and cellular agriculture infrastructure services. The latter category included contract research, media formulations, bioreactor systems, and consulting for other cell-ag companies navigating early R&D phases—essentially selling expertise to competitors still searching for their own paths to market.
All segments, the company noted, achieved positive unit economics.
It's a modest milestone by Silicon Valley standards, where profitability often takes a backseat to hypergrowth. But in an industry still hemorrhaging investor capital in search of elusive scale, it stood out. The Good Food Institute's report explicitly cited IntegriCulture as an example of diversification paying off, highlighting the company's ability to generate revenue from research tools and non-food products while the broader cultivated meat sector struggled to find its footing.
Hanyu's commentary was characteristically pragmatic. He noted that as long as cellular agriculture remains as capital-intensive as it currently is, scaling will remain difficult. The infrastructure business and cosmetics provided a bridge—financing continued R&D while the regulatory and economic fundamentals for cultivated food slowly, perhaps glacially, matured.
A Broader Shift
IntegriCulture isn't alone in exploring cosmetics as an alternative revenue stream, though it may be the furthest along. Avant Meats, originally a Hong Kong-based cultivated seafood startup, launched Zellulin, a cell-based functional protein for skincare, back in February 2021 and later spun out a BIOTECQ skincare brand. Even UPSIDE Foods, one of the most prominent cultivated meat companies in the United States, filed trademarks in 2025 for Lucius Labs indicating interest in cell culture media "for use in the cosmetic industry."
The broader trend, noted in industry analyses from Forward Fooding to Trends in Biotechnology, is that cultivated meat companies are pivoting toward B2B ingredients. Cosmetics represents one of the fastest regulatory pathways to market, with consumer demand for biotech-derived actives growing alongside interest in growth factors, collagen, and peptides. A 2026 beauty trends report from Spate showed strong year-over-year growth in consumer searches for these ingredients—evidence that the market might actually be there, waiting.
Whether this cosmetics detour becomes a permanent feature of the cellular agriculture landscape or just a bridge to eventual food applications remains unclear. What IntegriCulture has demonstrated—perhaps more clearly than any of its peers—is that survival in deep tech sometimes requires flexibility about the destination.
Hanyu and Kawashima set out to build infrastructure for a new food system. A decade later, they're profitable selling face cream and bioreactor expertise. The cultivated meat dream hasn't died. It's just sharing shelf space with something more immediately sellable, something consumers will actually buy today rather than someday. In an industry built on bold predictions and distant timelines, that kind of pragmatism might be the rarest ingredient of all.
